Search for a clinical trial
Other search option(s)
72 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
AUSTRIA
OBERÖSTERREICH
LINZ
A "window of opportunity" trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy (phase I-II)-AT
Kepler Universitätsklinikum - Med Campus III.
Universitätsklinik für Hämatologie und Internistische Onkologie
AUSTRIA
SALZBURG
SALZBURG
A "window of opportunity" trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy (phase I-II)-AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
AUSTRIA
TIROL
INNSBRUCK
A "window of opportunity" trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy (phase I-II)-AT
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
IMPRES Extension: An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
A "window of opportunity" trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy (phase I-II)-AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
DASCERN: An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy with 400 mg Imatinib - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
WIEN
ENESTg1: A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
AUSTRIA
WIEN
WIEN
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
BELGIUM
NAMUR
YVOIR
ENESTnd: A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) - BE
Cliniques Universitaires UCL de Mont-Godinne
Department of Hematology
BELGIUM
VLAAMS BRABANT
LEUVEN
IMPRES Extension: An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension - BE
UZ Leuven - Campus Gasthuisberg
Centrum pulmonale hypertensie/ Pulmonary hypertension center
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
IMPRES: A 24-week Randomized Placebo-controlled, Double-blind Multi-centre Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (PhaseIII)
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
ENESTcmr - An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-PCR (Phase III) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
IMPRES Extension - An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension(Phase III) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Non-randomized, Open-label Study to Characterize the Pharmacokinetics (PK) of Glivec/Gleevec® (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) or Other Glivec/ Gleevec® Indicated Hematological Disorders (HES, CEL, MDS/ MPN) - FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
LYON
ImadGist : A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
CLCC Léon Bérard
Cancérologie médicale - Sarcomes et GIST, Tumeurs rares
FRANCE
BRETAGNE
RENNES
ESPHALL: An open-label, randomized phase II-study to compare the safety and efficacy of imatinib with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) - FR
CHU de Rennes - Hôpital Sud
Consultations d'hémato-oncologie pédiatrique
FRANCE
NOUVELLE AQUITAINE
BORDEAUX
MIM : Phase III multicentric trial to evaluate the efficacy of a strategy of dose determination of imatinib mesilate on molecular response in patients with chronic phase of Chronic Myeloid Leukemia treated with imatinib mesilate 400 mg/day for two years, with complete cytogenetic response for at least one year.
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANCE
NOUVELLE AQUITAINE
PESSAC
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment - FR
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service d'hématologie et thérapie cellulaire
FRANCE
NOUVELLE AQUITAINE
PESSAC
STIM 2 : Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Laboratoire d'Hématologie - Secteur de cytogénétique et biologie moléculaire
GERMANY
Baden-Württemberg
FREIBURG
DECLINE (CAMN107ADE18T): Imatinib 400 mg daily versus Nilotinib 300 mg twice daily in patients with chronic myeloid leukemia (CML) in 1st chronic phase and confirmed major molecular response (MMR) receiving Imatinib at a dose of 400 mg daily. An open-label, randomized multicenter phase 3b study to determine the conversion rate from MMR to molecular response >= 4 log (MR4) after two years - DE
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
GERMANY
Baden-Württemberg
MANNHEIM
Phase II study to evaluate Glivec (imatinib mesylate) to induce progression arrest in aggressive Fibromatosis / desmoid tumors not amenable to surgical resection with R0 intent or accompanied by unacceptable function loss - DE - Completed
Universitätsmedizin Mannheim
Sarkom-Zentrum
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension -DE-
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones -DE-
Institution: Information not provided - DE
GERMANY
Niedersachsen
HANNOVER
A randomized, open label, multicenter phase III study to evaluate the efficacy and safety of Nilotinib versus Imatinib in adult patients with unresectable or metastatic Gastrointestinal Stromal Tumors (GIST)
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
GERMANY
Nordrhein-Westfalen
AACHEN
CHOICES: A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR) - DE
Universitätsklinikum Aachen
Klinik für Onkologie, Hämatologie und Stammzelltransplantation (Med. Klinik IV)
GERMANY
Thüringen
JENA
CML Imatinib Versus Nilotinib: A Phase III multicenter, open-label, randomized rtudy of Imatinib versus Nilotinib in adult patients with newly diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in chronic phase - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie
GERMANY
Thüringen
JENA
An open label phase II study of the combination of Imatinib and Lonafarnib in patients with CML in chronic phase and absence of good molecular remission - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie
GERMANY
Thüringen
JENA
A phase IV, open-label, multicenter study of Dasatinib in chronic-phase Chronic Myeloid Leukemia patients with chronic, low-grade non-hematologic toxicity to Imanitib - DE Completed
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie
ITALY
CAMPANIA
NAPOLI
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Azienda Ospedaliera Universitaria "Federico II"
U.O. di Ematologia e Trapianto di Cellule Staminali Emopoietiche
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones - EsPhALL2017/COGAALL1631 - IT
Institution: Information not provided - IT
ITALY
LOMBARDIA
MONZA
Long term side effects of imatinib on Chronic Myeloid Leukemia (CLM) patients.
ASST Monza - Ospedale San Gerardo
Unità di Ricerca Clinica
ITALY
LOMBARDIA
ROZZANO
A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma
IRCCS Istituto Clinico Humanitas
U.O. Oncologia Medica ed Ematologia
ITALY
MARCHE
ANCONA
Low-dose oral Imatinib in the treatment of Scleroderma pulmonary involvement: a phase II pilot sutdy
Università Politecnica delle Marche - Polo Didattico
Istituto di Clinica Medica
NETHERLANDS
Zuid-Holland
ROTTERDAM
Reduced intensity chemotherapy given with and without Imatinib Mesylate in patients >/= 60 years considered unfit for standard chemotherapy with previously untreated Acute Myeloid Leukemia (AML) and refractory anemia with excess of Blasts (RAEB, RAEB-T); A randomized phase II study.
Erasmus MC - Erasmus Medisch Centrum
Afdeling Hematologie
SPAIN
Aragón
ZARAGOZA
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV) (Phase IV) - ES (completed)
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPAIN
Aragón
ZARAGOZA
ENESTnd: A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) - ES (Completed)
Hospital Universitario Miguel Servet
Servicio de Hematología y Hemoterapia
SPAIN
Castilla - La Mancha
TOLEDO
Therapy with tyrosine kinase inhibitors in patients with poor-prognosis Systemic Mastocytosis: clinical trial in patients without D816V KIT mutation and search for KIT D816V+ inhibitors (Phase III) (completed)
Hospital Virgen del Valle
Instituto de Estudios de Mastocitosis de Castilla La Mancha
SPAIN
Cataluña
BADALONA
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) positive - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
SPAIN
Cataluña
BADALONA
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Oncología Médica
SPAIN
Cataluña
BARCELONA
SeliGIST: A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPAIN
Cataluña
SABADELL
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) - ES (Completed)
Corporación Sanitaria Parc Taulí. Hospital de Sabadell
Servicio de Oncología
SPAIN
Comunidad Valenciana
VALENCIA
Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib Mesylate (Glivec) Versus No Further Therapy After Complete Surgery (Phase III) (terminated)
Fundación Instituto Valenciano de Oncología (IVO)
Servicio de Oncología Médica
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
ENESTcmr: An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR (Phase III) - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis (Phase II) - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
Extension Study to a Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) - ES (Completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Single-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib - ES (completed)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An open-label, multi-center protocol to provide QTI571 to PAH patients who participated in one of the extension studies and are judged by the investigator to benefit from continued QTI571 treatment (Phase III) - ES (terminated)
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones - ES
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
IMPRES: A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (Phase III) (completed)
Hospital Universitario 12 de Octubre
Unidad Multidisciplinar de Hipertensión Pulmonar
SPAIN
Madrid
MADRID
IMPRES Extension: An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension (Phase III) (Completed)
Hospital Universitario 12 de Octubre
Unidad Multidisciplinar de Hipertensión Pulmonar
SPAIN
Madrid
MADRID
A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase - ES (terminated)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia
SPAIN
Madrid
MADRID
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) - ES (Completed)
Hospital Universitario La Paz
Servicio de Oncología Médica
SWITZERLAND
Suisse Alémanique
ZÜRICH
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones - CH
Universitäts - Kinderspital Zürich - Eleonorenstiftung
Onkologie
UNITED KINGDOM
Glasgow
GLASGOW
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis (Phase II) - UK
University of Glasgow, Kelvin Building
College of Medical, Veterinary & Life Sciences
UNITED KINGDOM
Glasgow
GLASGOW
Clinical trial for patients with TKI resistant chronic myeloid leukaemia in chronic or accelerated phase -GB
University of Glasgow, Kelvin Building
The University of Glasgow (Headquarters)
UNITED KINGDOM
Greater London
LONDON
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis (Phase II) - UK
Hammersmith Hospital
Leukaemia Cytogenetics Unit
UNITED KINGDOM
Greater London
SURREY
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment - GB
The Royal Marsden
Royal Marsden NHS Foundation Trust
UNITED KINGDOM
Greater London
UXBRIDGE
A Randomized, Placebo-controlled, Double-blind Study to Investigate the Effects of the Tyrosine Kinase Inhibitor Imatinib on Pulmonary Vascular Dysfunction in a Human Experimental Model of Acute Lung Injury
PAREXEL International Limited
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
CAMN107G2301: A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
IMPRES Extension:An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension (Phase III) - UK
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
MANCHESTER
Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery (Phase III) - UK
The Christie, NHS Foundation Trust
The Christie NHS Foundation Trust
UNITED KINGDOM
Merseyside
WIRRAL
ITEM: A phase II study of Imatinib in the treatment of patients with metastatic uveal melanoma
The Clatterbridge Cancer Centre NHS Foundation Trust
The Clatterbridge Cancer Centre
UNITED KINGDOM
Strathclyde
GLASGOW
Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery (Phase III) - UK
NHS Greater Glasgow and Clyde Corporate HQ
Greater Glasgow and Clyde NHS Board
UNITED KINGDOM
Surrey
CAMBERLEY
A phase III multi-center, open label, randomised study of optimised imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) - UK
Novartis Pharmaceuticals UK Limited
Novartis Pharmaceuticals
UNITED KINGDOM
Tyne & Wear
NEWCASTLE UPON TYNE
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis (Phase II) - UK
University of Newcastle
University of Newcastle Upon-Tyne
Multinational clinical trial(s)
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones - EsPhALL2017/COGAALL1631
Institution: Information not provided - IT
SWITZERLAND
Suisse Alémanique
BASEL
A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) (coordination)
Novartis International AG
SWITZERLAND
Suisse Alémanique
BASEL
SWITZERLAND
Suisse Alémanique
BASEL
An open-label, randomized phase II/III-study to compare the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) (coordination)
Novartis Pharma Services AG
SWITZERLAND
Suisse Alémanique
BASEL